HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: First, we tested if CPEB4 expression is enhanced by HDAC inhibitors in general, using the pan-HDAC inhibitor Trichostatin A (TSA) and the structurally related suberoylanilide hydroxamic acid (SAHA), an FDA-approved HDAC inhibitor used for the treatment of refractory cutaneous T-cell lymphoma [66].